NEW YORK, April 23 – Knockout-mouse company Exelixis has agreed to acquire Germany’s Artemis Pharmaceuticals, in a stock-for-stock transaction valued at more than $24 million, the companies said Monday.

"The industry has come to realize the power of identifying and validating targets in living organisms where complex functional relationships that are too complicated or unexpected to predict by other methods can be identified,” George Scangos, Exelixis CEO, said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.